Nature Reviews Neurology - Table of Contents alert Volume 12 Issue 8

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
August 2016 Volume 12 Number 8
Impact Factor 18.418 *	In this issue Research Highlights News and Views Reviews Perspectives Also this month  Featured article: Vascular endothelial growth factor: a neurovascular target in neurological diseases Christian Lange, Erik Storkebaum, Carmen Ruiz de Almodóvar, Mieke Dewerchin & Peter Carmeliet
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
An open access journal dedicated to highlighting the most important scientific advances in Parkinson's disease research, spanning the motor and non-motor disorders of Parkinson's disease. Part of the Nature Partner Journals series, npj Parkinson's Disease is published in partnership with the Parkinson's Disease Foundation.  Open for submissions
Advertisement
Open for Submissions A new open access, multi- and interdisciplinary journal dedicated to publishing the highest quality papers on aging and age-related diseases, the journal is now open for submissions. Explore the benefits of submitting your next research.
RESEARCH HIGHLIGHTS Top Multiple sclerosis: Immune reconstitution effective for MS Published online: 24 June 2016 p429 | doi:10.1038/nrneurol.2016.96 PDF Neurodegenerative disease: Glial cells — friend and foe in Huntington disease? Published online: 24 June 2016 p430 | doi:10.1038/nrneurol.2016.95 PDF Neurodevelopmental disorders: Impaired immune system function linked to social behaviour deficits in mice Published online: 22 July 2016 p431 | doi:10.1038/nrneurol.2016.109 PDF Alzheimer disease: Could tear proteins be biomarkers for Alzheimer disease? Published online: 08 July 2016 p432 | doi:10.1038/nrneurol.2016.104 PDF Stroke: Virtual reality no better than simple recreational activity in stroke recovery Published online: 15 July 2016 p432 | doi:10.1038/nrneurol.2016.108 PDF Cerebrovascular disorders: Cerebral microbleeds linked to increased risk of cognitive decline Published online: 24 June 2016 p432 | doi:10.1038/nrneurol.2016.94 PDF IN BRIEF Neurodevelopmental disorders: Epilepsy and autism spectrum disorders may have a shared aetiology | Parkinson disease: No diagnostic value of α-synuclein staining of the colon mucosa in idiopathic Parkinson disease | Alzheimer disease: Elevated neurogranin levels reveal early synaptic damage in APOE* ϵ4 carriers | Neuromuscular disease: Methotrexate has no steroid-sparing effect in patients with generalized myasthenia gravis PDF Nature Reviews Neurology JOBS of the week Director of Neurology Clinical Science UCB Pharma Ltd. More Science jobs from Nature Reviews Neurology EVENT The Lancet Neurology Conference: Preclinical neurodegenerative disease – towards prevention and early diagnosis 19.10.16 London, UK More science events from
NEWS AND VIEWS		Top
Alzheimer disease: Host immune defence, amyloid-β peptide and Alzheimer disease Todd E. Golde Published online: 15 July 2016 p433 | doi:10.1038/nrneurol.2016.105 A recent study demonstrates that amyloid-β (Aβ) can function as an antimicrobial peptide, and additional data show that bacteria and yeast can seed Aβ deposition into amyloid. These data suggest a complex interplay between the normal function of Aβ, its accumulation in the brain, and host immune defence. Full Text | PDF
Stroke: How good is aspirin for patients with acute brain ischaemia? Robert G. Hart & John W. Eikelboom Published online: 08 July 2016 p434 | doi:10.1038/nrneurol.2016.97 A new meta-analysis, which evaluated individual patient data from randomized trials of aspirin in patients with non-disabling acute brain ischaemia, found this drug to be much more efficacious at reducing early stroke recurrence than was previously estimated. Full Text | PDF
Multiple sclerosis: Dimethyl fumarate is coming of age Mar Tintoré & Jaume Sastre-Garriga Published online: 22 July 2016 p436 | doi:10.1038/nrneurol.2016.106 Recently published findings from the ENDORSE study provide 5 years of randomized safety and efficacy data for two doses of dimethyl fumarate (DMF) in multiple sclerosis. The report complements results from the pivotal CONFIRM and DEFINE trials; however, postmarketing data from clinical practice is needed to complete the risk-benefit profile of DMF. Full Text | PDF
REVIEWS		Top
Vascular endothelial growth factor: a neurovascular target in neurological diseases Christian Lange, Erik Storkebaum, Carmen Ruiz de Almodóvar, Mieke Dewerchin & Peter Carmeliet Published online: 01 July 2016 p439 | doi:10.1038/nrneurol.2016.88 The archetypal vascular endothelial growth factor, VEGF, arose in evolution as a signal affecting neural cells, and was subsequently co-opted to regulate vascular function. Here, the authors review the roles of the VEGF family as both aetiological factors and therapeutic targets in neurological disease. Abstract | Full Text | PDF
Chronic migraine: risk factors, mechanisms and treatment Arne May & Laura H. Schulte Published online: 08 July 2016 p455 | doi:10.1038/nrneurol.2016.93 About 2% of the general population and 8% of people with migraine have chronic migraine, defined as ≥15 headache days per month. The condition can be disabling and has a severe impact on quality of life, yet it receives little attention. This Review summarizes the current understanding of the risk factors and pathophysiological mechanisms of migraine chronification, and discusses strategies to prevent and treat the disorder. Abstract | Full Text | PDF
Cognitive and neurodevelopmental comorbidities in paediatric epilepsy Katherine C. Nickels, Michael J. Zaccariello, Lorie D. Hamiwka & Elaine C. Wirrell Published online: 22 July 2016 p465 | doi:10.1038/nrneurol.2016.98 Cognitive and behavioural comorbidities are common in children with epilepsy, and correlate with worse quality of life, increased behavioural and language problems and worse social skills, all of which adversely affect long-term psychosocial functioning. This review outlines the most common cognitive comorbidities in different types of epilepsy, and outlines the current understanding of the pathophysiology of epilepsy-associated cognitive and neurodevelopmental problems in children with epilepsy. Moreover, the authors provide suggestions for screening for cognitive comorbidity in this patient group. Abstract | Full Text | PDF
The Glasgow Outcome Scale — 40 years of application and refinement Tom McMillan, Lindsay Wilson, Jennie Ponsford, Harvey Levin, Graham Teasdale & Michael Bond Published online: 15 July 2016 p477 | doi:10.1038/nrneurol.2016.89 The Glasgow Outcome Scale (GOS) is widely recommended as an outcome measure after traumatic brain injury. Following the 40th anniversary of its original publication, McMillan and colleagues review the development of the GOS and its extension and refinement over the past four decades, and consider how it can contribute to further understanding of brain injury. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Sports-related concussions — media, science and policy Rebekah Mannix, William P. Meehan III & Alvaro Pascual-Leone Published online: 01 July 2016 p486 | doi:10.1038/nrneurol.2016.99 Participants in collision sports show a high incidence of concussion and can have deleterious long-term consequences for brain function. Here, Rebekah Mannix and colleagues discuss the benefits and risks associated with the practice of contact sports and examine how this balance affects policies regarding the practice of collision sports. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2016. Nature Reviews Neurology was previously published as Nature Clinical Practice Neurology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.